|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Seven factors were associated with ICAS, as suggested by the meta-analysis, including advanced age (odds ratio (OR) 1.05, 95% CI 1.03-1.08), metabolic syndrome (OR 2.13, 95% CI 1.35-3.37), diabetes mellitus (OR 1.98, 95% CI 1.69-2.31), hypertension (OR 1.97, 95% CI 1.69-2.31), dyslipidemia (OR 1.29, 95% CI 1.04-1.59), high levels of low-density lipoprotein cholesterol (OR 1.06, 95% CI 1.00-1.12) and high levels of apolipoprotein A1 (OR 0.34, 95% CI 0.15-0.75).
|
30658194 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interestingly, JUN was a putative target of LGZGD and APOA1 is one of the known targets of both MetS and SGAs (olanzapine and clozapine).
|
31085379 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Implication of the rs670 variant of APOA1 gene with lipid profile, serum adipokine levels and components of metabolic syndrome in adult obese subjects.
|
29277345 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, 54.5% met diagnostic criteria for metabolic syndrome (MS) and displayed higher SBP, BMI-SDS, fat mass (FM), HOMA-IR, hs-CRP, TG, TC/HDL, TG/HDL, ApoB/ApoA-1, and HbA<sub>1c</sub>, but lower HDL and ApoA-1 than the non-MS group (P < 0.05) with similar gender distribution.
|
29154726 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The western DP had a significant interaction with APOC3, APOA1 and MC4R polymorphisms in relation to MetS.
|
30584439 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In contrast, patients with higher levels of ApoA1 (OR: 0.73, 95% CI [0.67,0.79]), Metabolic Syndrome (OR: 0.64, 95% CI [0.53, 0.76]), higher CV risk (OR: 0.33, 95% CI 0.27, 0.41), those who forgot to take their medication (OR: 0.74, 95% CI 0.62,0.88) and those who stopped taking medication when cholesterol became normal (OR: 0.67, 95% CI 0.55,0.82) were significantly associated with lower odds of attaining LDL-C target.
|
28677510 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
We investigated the association between the apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio and insulin resistance (IR), metabolic syndrome (MS) and its components in Chinese polycystic ovary syndrome (PCOS) adults.
|
28413474 |
2017 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.
|
26824674 |
2016 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Compared with other genotype combinations, the combined effect of APOC3/APOA1 (CC/GA+AA/CT+TT) genotypes showed a further increase in the risk of the MetS in the highest quartile of WDP scores (OR 1, 2·49, 8·73, 6·32, P trend< 0·001, P(interaction)= 0·003).
|
25653052 |
2015 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the effects of a promoter polymorphism (-75G>A) in the APOA1 gene on metabolic syndrome (MetS) components in a Turkish population sample.
|
24508624 |
2014 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
The logarithm of the ratio of plasma concentration of triglycerides to HDL-cholesterol [log(TG-to-HDL-C)], waist circumference, systolic blood pressure, apolipoprotein A1, glucose and alanin aminotransferase accounted for most of the differences in MetS manifestation.
|
23215737 |
2013 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A previously known lipid locus, APOA1/C3/A4/A5 gene cluster region (SNP rs964184), was associated with MetS in all 4 study samples (P=7.23×10(-9) in meta-analysis).
|
22399527 |
2012 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The goal is to identify Apo lipoprotein A1 (APOA1) gene polymorphisms and their association with CAD risk factors, metabolic syndrome and dysfunctional HDL (Dys-HDL).
|
22297598 |
2012 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
ApoB rs512535 and ApoA1 rs670 may influence MetS risk.
|
21122859 |
2011 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Reduced plasma HDL and ApoA-I levels have been found to be associated with obesity and metabolic syndrome in human beings.
|
20193037 |
2011 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
On multi-variate analysis, MS was significantly associated with BMI > 23 (P = 0.005), Apo-A-I levels (p = 0.01), and Lp [a] (p < 0.0001).
|
21410987 |
2011 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
|
18988892 |
2009 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The variant was significantly associated not only with decreased HDL cholesterol and apolipoprotein A-I levels but also with obesity (odds ratio 2.527, P = 0.005), the metabolic syndrome (1.893, P = 0.0007), and type 2 diabetes (4.527, P = 0.003).
|
17287470 |
2007 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein B (apoB) is associated with MetS by multiple logistic analysis with an OR of 1.05 (1.03-1.07, P<0.001) in FCHL families, OR of 1.26 (1.03-1.55, P=0.026) in FHTG and OR of 1.07 (1.01-1.12, P=0.014) in FH families, independent of variables including age, gender, apolipoprotein A1, and low density lipoprotein cholesterol.
|
16828905 |
2007 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
RGD |
Diversity of metabolic syndrome risk factors in obese children and adolescents.
|
17217166 |
2006 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Low HDL cholesterol and apolipoprotein A-I levels often are found in association with other cardiovascular risk factors, including the metabolic syndrome, insulin resistance, and type 2 diabetes mellitus.
|
12957326 |
2003 |